Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ERAS-0015 · 1 trial · 1 indication
Based on toxicities observed
Based on toxicities observed
Based on toxicities observed
Incidence and severity of treatment-emergent AEs and serious AEs
Maximum plasma concentration of ERAS-0015
Time to achieve maximum plasma concentration of ERAS-0015
Area under the plasma concentration-time curve of ERAS-0015
Half-life of ERAS-0015
| Arm | Type | Description |
|---|---|---|
| ERAS-0015 Monotherapy Dose Optimization. | EXPERIMENTAL | Escalating doses of ERAS-0015 administered orally. |
| ERAS-0015 Combination Dose Optimization | EXPERIMENTAL | ERAS-0015 administered orally with another investigational agent. |
| Name | Type | Description |
|---|---|---|
| ERAS-0015 | DRUG | ERAS-0015 Administered orally |
| ERAS-0015 in combination | DRUG | ERAS-0015 Administered orally and in combination with either KEYTRUDA® (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration. |
Inclusion Criteria: * Age ≥ 18 years * Willing and able to give written informed consent * Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts. * There is no available standard systemic therapy available for the patient's tumor hist...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ERAS-0015 is an investigational small molecule being developed by Erasca, Inc. for the treatment of advanced or metastatic solid tumors. It is currently in Phase 1 clinical development and is not yet approved for any indication. It is being studied in adult patients with metastatic solid tumors.
ERAS-0015 is being studied for the treatment of advanced or metastatic solid tumors. It is an investigational therapy in Phase 1 development and has not been approved for commercial use. The ongoing trial enrolls adults 18 years and older with metastatic solid tumors.
ERAS-0015 targets RAS, a gene that encodes proteins involved in cell signaling and growth. RAS mutations are common in cancer, and ERAS-0015 is a small molecule designed to act on this target. It is being evaluated in patients with advanced or metastatic solid tumors.
ERAS-0015 is being developed by Erasca, Inc., a biopharmaceutical company whose common stock trades under the ticker symbol ERAS. Erasca is the sponsor of the Phase 1 clinical trial evaluating ERAS-0015 in patients with advanced or metastatic solid tumors.
ERAS-0015 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 1 trial is currently recruiting participants with advanced or metastatic solid tumors.
ERAS-0015 is being evaluated in one active clinical trial, NCT06983743, titled A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors. The trial is a Phase 1 study that is currently recruiting, with a planned enrollment of 600 participants, and it is being conducted in the United States.